✓ Translated by DotMD AI Clinical Council Source: Journal of drugs in dermatology : JDD • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #33852251 ↗

Phase III Randomized Trial: A Phase 3, Randomized Trial Demonstrating the Improved Efficacy and Patient Acceptability of Fixed Dose Calcipotriene and Betamethasone Dipropionate Cream (N = 796)

Original Paper Title: “A Phase 3, Randomized Trial Demonstrating the Improved Efficacy and Patient Acceptability of Fixed Dose Calcipotriene and Betamethasone Dipropionate Cream”

Elena Rostova (AI Quant) Rigor Score
87 / 100
Sample Size (Participants)
N = 796
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • CAL/BDP cream is a novel topical treatment of psoriasis, which in a single product, offers a unique combination of high efficacy combined with favorable safety and excellent treatment convenience. For these reasons, CAL/BDP cream offers a distinctive advantage for the topical treatment of plaque psoriasis.
  • Study Design & Sample: Phase III Randomized Trial published in Journal of drugs in dermatology : JDD (N = 796 human participants).
  • Biostatistical Rigor Score: 87/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Journal of drugs in dermatology : JDD (2021), this phase iii randomized trial evaluating 796 human participants investigated: The fixed dose combination of calcipotriene and betamethasone dipropionate (CAL/BDP) is a well-established, efficacious, and safe topical treatment of psoriasis. Key clinical takeaway: CAL/BDP cream is a novel topical treatment of psoriasis, which in a single product, offers a unique combination of high efficacy combined with favorable safety and excellent treatment convenience. For these reasons, CAL/BDP cream offers a distinctive advantage for the topical treatment of plaque psoriasis.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Journal of drugs in dermatology : JDD, 2021-04-01; N = 796; Rigor 87/100): CAL/BDP cream is a novel topical treatment of psoriasis, which in a single product, offers a unique combination of high efficacy combined with favorable safety and excellent treatment convenience. For these reasons, CAL/BDP cream offers a distinctive advantage for the topical treatment of plaque psoriasis.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: calcipotriene → Rx: calcipotriene-betamethasone-dipropionate → Rx: betamethasone-dipropionate → Rx: betamethasone-valerate-foam → Condition: other-seborrheic-dermatitis → Condition: allergic-contact-dermatitis-due-to-metals →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 33852251: Phase III Randomized Trial: A Phase 3, Randomized Trial Demonstrating the Improved Efficacy and Patient Acceptability of Fixed Dose Calcipotriene and Betamethasone Dipropionate Cream (N = 796)

3 of 3 Free Questions Remaining